US COVID-19 hospitalizations surge to record level

The number of Covid-19 infections in the US surpassed 10.4 million, with over 59 thousand patients in hospitals. This is the highest number of hospitalizations since July, as number of new infections continues to surge across the country. Over the last 24 hours, the US reported around 120 thousand new cases.

 

Meanwhile US Food and Drug Administration (FDA) has authorized the emergency use of Eli Lilly’s (LLY.US) experimental COVID-19 antibody treatment bamlanivimab for non-hospitalized patients with mild-to-moderate symptoms. New treatment reduces the need for hospitalization or emergency room visits in COVID-19 patients at high risk of the disease worsening.

The number of Americans with COVID-19 currently hospitalized has surged around 73% over the past 30 days to at least 59,275. Source: The COVID Tracking Project.

Eli Lilly’s (LLY.US) stock jumped over 3% in pre-market and is currently testing strong resistance at $148.00 which is additionally strengthened by 200 SMA (red line). If the current sentiment prevails, the upward move could be extended to the next resistance at $157.44. On the other hand local support lies at $139.21. Source: xStation5

The content of this report has been created by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, (KRS number 0000217580) and supervised by Polish Supervision Authority ( No. DDM-M-4021-57-1/2005). This material is a marketing communication within the meaning of Art. 24 (3) of Directive 2014/65/EU of the European Parliament and of the Council of 15 May 2014 on markets in financial instruments and amending Directive 2002/92/EC and Directive 2011/61/EU (MiFID II). Marketing communication is not an investment recommendation or information recommending or suggesting an investment strategy within the meaning of Regulation (EU) No 596/2014 of the European Parliament and of the Council of 16 April 2014 on market abuse (market abuse regulation) and repealing Directive 2003/6/EC of the European Parliament and of the Council and Commission Directives 2003/124/EC, 2003/125/EC and 2004/72/EC and Commission Delegated Regulation (EU) 2016/958 of 9 March 2016 supplementing Regulation (EU) No 596/2014 of the European Parliament and of the Council with regard to regulatory technical standards for the technical arrangements for objective presentation of investment recommendations or other information recommending or suggesting an investment strategy and for disclosure of particular interests or indications of conflicts of interest or any other advice, including in the area of investment advisory, within the meaning of the Trading in Financial Instruments Act of 29 July 2005 (i.e. Journal of Laws 2019, item 875, as amended). The marketing communication is prepared with the highest diligence, objectivity, presents the facts known to the author on the date of preparation and is devoid of any evaluation elements. The marketing communication is prepared without considering the client’s needs, his individual financial situation and does not present any investment strategy in any way. The marketing communication does not constitute an offer of sale, offering, subscription, invitation to purchase, advertisement or promotion of any financial instruments. XTB S.A. is not liable for any client’s actions or omissions, in particular for the acquisition or disposal of financial instruments, undertaken on the basis of the information contained in this marketing communication. In the event that the marketing communication contains any information about any results regarding the financial instruments indicated therein, these do not constitute any guarantee or forecast regarding the future results.